img

Global PARP Inhibitors for Cancer Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global PARP Inhibitors for Cancer Market Insights, Forecast to 2034

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
Global PARP Inhibitors for Cancer market is expected to reach to US$ 7815.3 million in 2024, with a positive growth of %, compared with US$ 5904.1 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, PARP Inhibitors for Cancer industry is evaluated to reach US$ 13040 million in 2029. The CAGR will be 8.9% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global PARP Inhibitors for Cancer market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global PARP Inhibitors for Cancer market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other

Segment by Application


Ovarian Cancer
Breast Cancer
Other

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ PARP Inhibitors for Cancer plant distribution, commercial date of PARP Inhibitors for Cancer, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, PARP Inhibitors for Cancer introduction, etc. PARP Inhibitors for Cancer Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of PARP Inhibitors for Cancer
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 PARP Inhibitors for Cancer Product Introduction
1.2 Market by Type
1.2.1 Global PARP Inhibitors for Cancer Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 Market by Application
1.3.1 Global PARP Inhibitors for Cancer Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global PARP Inhibitors for Cancer Sales Estimates and Forecasts 2018-2029
2.2 Global PARP Inhibitors for Cancer Revenue by Region
2.2.1 Global PARP Inhibitors for Cancer Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global PARP Inhibitors for Cancer Revenue by Region (2018-2024)
2.2.3 Global PARP Inhibitors for Cancer Revenue by Region (2024-2029)
2.2.4 Global PARP Inhibitors for Cancer Revenue Market Share by Region (2018-2029)
2.3 Global PARP Inhibitors for Cancer Sales Estimates and Forecasts 2018-2029
2.4 Global PARP Inhibitors for Cancer Sales by Region
2.4.1 Global PARP Inhibitors for Cancer Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global PARP Inhibitors for Cancer Sales by Region (2018-2024)
2.4.3 Global PARP Inhibitors for Cancer Sales by Region (2024-2029)
2.4.4 Global PARP Inhibitors for Cancer Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global PARP Inhibitors for Cancer Sales by Manufacturers
3.1.1 Global PARP Inhibitors for Cancer Sales by Manufacturers (2018-2024)
3.1.2 Global PARP Inhibitors for Cancer Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of PARP Inhibitors for Cancer in 2022
3.2 Global PARP Inhibitors for Cancer Revenue by Manufacturers
3.2.1 Global PARP Inhibitors for Cancer Revenue by Manufacturers (2018-2024)
3.2.2 Global PARP Inhibitors for Cancer Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by PARP Inhibitors for Cancer Revenue in 2022
3.3 Global Key Players of PARP Inhibitors for Cancer, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global PARP Inhibitors for Cancer Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global PARP Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of PARP Inhibitors for Cancer, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of PARP Inhibitors for Cancer, Product Offered and Application
3.8 Global Key Manufacturers of PARP Inhibitors for Cancer, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global PARP Inhibitors for Cancer Sales by Type
4.1.1 Global PARP Inhibitors for Cancer Historical Sales by Type (2018-2024)
4.1.2 Global PARP Inhibitors for Cancer Forecasted Sales by Type (2024-2029)
4.1.3 Global PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
4.2 Global PARP Inhibitors for Cancer Revenue by Type
4.2.1 Global PARP Inhibitors for Cancer Historical Revenue by Type (2018-2024)
4.2.2 Global PARP Inhibitors for Cancer Forecasted Revenue by Type (2024-2029)
4.2.3 Global PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
4.3 Global PARP Inhibitors for Cancer Price by Type
4.3.1 Global PARP Inhibitors for Cancer Price by Type (2018-2024)
4.3.2 Global PARP Inhibitors for Cancer Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global PARP Inhibitors for Cancer Sales by Application
5.1.1 Global PARP Inhibitors for Cancer Historical Sales by Application (2018-2024)
5.1.2 Global PARP Inhibitors for Cancer Forecasted Sales by Application (2024-2029)
5.1.3 Global PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
5.2 Global PARP Inhibitors for Cancer Revenue by Application
5.2.1 Global PARP Inhibitors for Cancer Historical Revenue by Application (2018-2024)
5.2.2 Global PARP Inhibitors for Cancer Forecasted Revenue by Application (2024-2029)
5.2.3 Global PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
5.3 Global PARP Inhibitors for Cancer Price by Application
5.3.1 Global PARP Inhibitors for Cancer Price by Application (2018-2024)
5.3.2 Global PARP Inhibitors for Cancer Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada PARP Inhibitors for Cancer Market Size by Type
6.1.1 US & Canada PARP Inhibitors for Cancer Sales by Type (2018-2029)
6.1.2 US & Canada PARP Inhibitors for Cancer Revenue by Type (2018-2029)
6.2 US & Canada PARP Inhibitors for Cancer Market Size by Application
6.2.1 US & Canada PARP Inhibitors for Cancer Sales by Application (2018-2029)
6.2.2 US & Canada PARP Inhibitors for Cancer Revenue by Application (2018-2029)
6.3 US & Canada PARP Inhibitors for Cancer Market Size by Country
6.3.1 US & Canada PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada PARP Inhibitors for Cancer Sales by Country (2018-2029)
6.3.3 US & Canada PARP Inhibitors for Cancer Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe PARP Inhibitors for Cancer Market Size by Type
7.1.1 Europe PARP Inhibitors for Cancer Sales by Type (2018-2029)
7.1.2 Europe PARP Inhibitors for Cancer Revenue by Type (2018-2029)
7.2 Europe PARP Inhibitors for Cancer Market Size by Application
7.2.1 Europe PARP Inhibitors for Cancer Sales by Application (2018-2029)
7.2.2 Europe PARP Inhibitors for Cancer Revenue by Application (2018-2029)
7.3 Europe PARP Inhibitors for Cancer Market Size by Country
7.3.1 Europe PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe PARP Inhibitors for Cancer Sales by Country (2018-2029)
7.3.3 Europe PARP Inhibitors for Cancer Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China PARP Inhibitors for Cancer Market Size
8.1.1 China PARP Inhibitors for Cancer Sales (2018-2029)
8.1.2 China PARP Inhibitors for Cancer Revenue (2018-2029)
8.2 China PARP Inhibitors for Cancer Market Size by Application
8.2.1 China PARP Inhibitors for Cancer Sales by Application (2018-2029)
8.2.2 China PARP Inhibitors for Cancer Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia PARP Inhibitors for Cancer Market Size by Type
9.1.1 Asia PARP Inhibitors for Cancer Sales by Type (2018-2029)
9.1.2 Asia PARP Inhibitors for Cancer Revenue by Type (2018-2029)
9.2 Asia PARP Inhibitors for Cancer Market Size by Application
9.2.1 Asia PARP Inhibitors for Cancer Sales by Application (2018-2029)
9.2.2 Asia PARP Inhibitors for Cancer Revenue by Application (2018-2029)
9.3 Asia PARP Inhibitors for Cancer Sales by Region
9.3.1 Asia PARP Inhibitors for Cancer Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia PARP Inhibitors for Cancer Revenue by Region (2018-2029)
9.3.3 Asia PARP Inhibitors for Cancer Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America PARP Inhibitors for Cancer Market Size by Type
10.1.1 Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America PARP Inhibitors for Cancer Market Size by Application
10.2.1 Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Country
10.3.1 Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 AstraZeneca PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Tesaro
11.2.1 Tesaro Company Information
11.2.2 Tesaro Overview
11.2.3 Tesaro PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Tesaro PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Tesaro Recent Developments
11.3 Merck & Co
11.3.1 Merck & Co Company Information
11.3.2 Merck & Co Overview
11.3.3 Merck & Co PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Merck & Co PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck & Co Recent Developments
11.4 Clovis Oncology
11.4.1 Clovis Oncology Company Information
11.4.2 Clovis Oncology Overview
11.4.3 Clovis Oncology PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Clovis Oncology PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Clovis Oncology Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Overview
11.5.3 Pfizer PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Pfizer PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Pfizer Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 PARP Inhibitors for Cancer Industry Chain Analysis
12.2 PARP Inhibitors for Cancer Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 PARP Inhibitors for Cancer Production Mode & Process
12.4 PARP Inhibitors for Cancer Sales and Marketing
12.4.1 PARP Inhibitors for Cancer Sales Channels
12.4.2 PARP Inhibitors for Cancer Distributors
12.5 PARP Inhibitors for Cancer Customers
13 Market Dynamics
13.1 PARP Inhibitors for Cancer Industry Trends
13.2 PARP Inhibitors for Cancer Market Drivers
13.3 PARP Inhibitors for Cancer Market Challenges
13.4 PARP Inhibitors for Cancer Market Restraints
14 Key Findings in The Global PARP Inhibitors for Cancer Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global PARP Inhibitors for Cancer Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Lynparza
Table 3. Major Manufacturers of Zejula
Table 4. Major Manufacturers of Rubraca
Table 5. Major Manufacturers of Talzenna
Table 6. Major Manufacturers of Other
Table 7. Global PARP Inhibitors for Cancer Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global PARP Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 9. Global PARP Inhibitors for Cancer Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global PARP Inhibitors for Cancer Revenue by Region (2024-2029) & (US$ Million)
Table 11. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2018-2024)
Table 12. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2024-2029)
Table 13. Global PARP Inhibitors for Cancer Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 14. Global PARP Inhibitors for Cancer Sales by Region (2018-2024) & (K Units)
Table 15. Global PARP Inhibitors for Cancer Sales by Region (2024-2029) & (K Units)
Table 16. Global PARP Inhibitors for Cancer Sales Market Share by Region (2018-2024)
Table 17. Global PARP Inhibitors for Cancer Sales Market Share by Region (2024-2029)
Table 18. Global PARP Inhibitors for Cancer Sales by Manufacturers (2018-2024) & (K Units)
Table 19. Global PARP Inhibitors for Cancer Sales Share by Manufacturers (2018-2024)
Table 20. Global PARP Inhibitors for Cancer Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 21. Global PARP Inhibitors for Cancer Revenue Share by Manufacturers (2018-2024)
Table 22. Global Key Players of PARP Inhibitors for Cancer, Industry Ranking, 2021 VS 2022 VS 2024
Table 23. PARP Inhibitors for Cancer Price by Manufacturers 2018-2024 (US$/Unit)
Table 24. Global PARP Inhibitors for Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global PARP Inhibitors for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP Inhibitors for Cancer as of 2022)
Table 26. Global Key Manufacturers of PARP Inhibitors for Cancer, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of PARP Inhibitors for Cancer, Product Offered and Application
Table 28. Global Key Manufacturers of PARP Inhibitors for Cancer, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global PARP Inhibitors for Cancer Sales by Type (2018-2024) & (K Units)
Table 31. Global PARP Inhibitors for Cancer Sales by Type (2024-2029) & (K Units)
Table 32. Global PARP Inhibitors for Cancer Sales Share by Type (2018-2024)
Table 33. Global PARP Inhibitors for Cancer Sales Share by Type (2024-2029)
Table 34. Global PARP Inhibitors for Cancer Revenue by Type (2018-2024) & (US$ Million)
Table 35. Global PARP Inhibitors for Cancer Revenue by Type (2024-2029) & (US$ Million)
Table 36. Global PARP Inhibitors for Cancer Revenue Share by Type (2018-2024)
Table 37. Global PARP Inhibitors for Cancer Revenue Share by Type (2024-2029)
Table 38. PARP Inhibitors for Cancer Price by Type (2018-2024) & (US$/Unit)
Table 39. Global PARP Inhibitors for Cancer Price Forecast by Type (2024-2029) & (US$/Unit)
Table 40. Global PARP Inhibitors for Cancer Sales by Application (2018-2024) & (K Units)
Table 41. Global PARP Inhibitors for Cancer Sales by Application (2024-2029) & (K Units)
Table 42. Global PARP Inhibitors for Cancer Sales Share by Application (2018-2024)
Table 43. Global PARP Inhibitors for Cancer Sales Share by Application (2024-2029)
Table 44. Global PARP Inhibitors for Cancer Revenue by Application (2018-2024) & (US$ Million)
Table 45. Global PARP Inhibitors for Cancer Revenue by Application (2024-2029) & (US$ Million)
Table 46. Global PARP Inhibitors for Cancer Revenue Share by Application (2018-2024)
Table 47. Global PARP Inhibitors for Cancer Revenue Share by Application (2024-2029)
Table 48. PARP Inhibitors for Cancer Price by Application (2018-2024) & (US$/Unit)
Table 49. Global PARP Inhibitors for Cancer Price Forecast by Application (2024-2029) & (US$/Unit)
Table 50. US & Canada PARP Inhibitors for Cancer Sales by Type (2018-2024) & (K Units)
Table 51. US & Canada PARP Inhibitors for Cancer Sales by Type (2024-2029) & (K Units)
Table 52. US & Canada PARP Inhibitors for Cancer Revenue by Type (2018-2024) & (US$ Million)
Table 53. US & Canada PARP Inhibitors for Cancer Revenue by Type (2024-2029) & (US$ Million)
Table 54. US & Canada PARP Inhibitors for Cancer Sales by Application (2018-2024) & (K Units)
Table 55. US & Canada PARP Inhibitors for Cancer Sales by Application (2024-2029) & (K Units)
Table 56. US & Canada PARP Inhibitors for Cancer Revenue by Application (2018-2024) & (US$ Million)
Table 57. US & Canada PARP Inhibitors for Cancer Revenue by Application (2024-2029) & (US$ Million)
Table 58. US & Canada PARP Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 59. US & Canada PARP Inhibitors for Cancer Revenue by Country (2018-2024) & (US$ Million)
Table 60. US & Canada PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 61. US & Canada PARP Inhibitors for Cancer Sales by Country (2018-2024) & (K Units)
Table 62. US & Canada PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 63. Europe PARP Inhibitors for Cancer Sales by Type (2018-2024) & (K Units)
Table 64. Europe PARP Inhibitors for Cancer Sales by Type (2024-2029) & (K Units)
Table 65. Europe PARP Inhibitors for Cancer Revenue by Type (2018-2024) & (US$ Million)
Table 66. Europe PARP Inhibitors for Cancer Revenue by Type (2024-2029) & (US$ Million)
Table 67. Europe PARP Inhibitors for Cancer Sales by Application (2018-2024) & (K Units)
Table 68. Europe PARP Inhibitors for Cancer Sales by Application (2024-2029) & (K Units)
Table 69. Europe PARP Inhibitors for Cancer Revenue by Application (2018-2024) & (US$ Million)
Table 70. Europe PARP Inhibitors for Cancer Revenue by Application (2024-2029) & (US$ Million)
Table 71. Europe PARP Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 72. Europe PARP Inhibitors for Cancer Revenue by Country (2018-2024) & (US$ Million)
Table 73. Europe PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 74. Europe PARP Inhibitors for Cancer Sales by Country (2018-2024) & (K Units)
Table 75. Europe PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 76. China PARP Inhibitors for Cancer Sales by Type (2018-2024) & (K Units)
Table 77. China PARP Inhibitors for Cancer Sales by Type (2024-2029) & (K Units)
Table 78. China PARP Inhibitors for Cancer Revenue by Type (2018-2024) & (US$ Million)
Table 79. China PARP Inhibitors for Cancer Revenue by Type (2024-2029) & (US$ Million)
Table 80. China PARP Inhibitors for Cancer Sales by Application (2018-2024) & (K Units)
Table 81. China PARP Inhibitors for Cancer Sales by Application (2024-2029) & (K Units)
Table 82. China PARP Inhibitors for Cancer Revenue by Application (2018-2024) & (US$ Million)
Table 83. China PARP Inhibitors for Cancer Revenue by Application (2024-2029) & (US$ Million)
Table 84. Asia PARP Inhibitors for Cancer Sales by Type (2018-2024) & (K Units)
Table 85. Asia PARP Inhibitors for Cancer Sales by Type (2024-2029) & (K Units)
Table 86. Asia PARP Inhibitors for Cancer Revenue by Type (2018-2024) & (US$ Million)
Table 87. Asia PARP Inhibitors for Cancer Revenue by Type (2024-2029) & (US$ Million)
Table 88. Asia PARP Inhibitors for Cancer Sales by Application (2018-2024) & (K Units)
Table 89. Asia PARP Inhibitors for Cancer Sales by Application (2024-2029) & (K Units)
Table 90. Asia PARP Inhibitors for Cancer Revenue by Application (2018-2024) & (US$ Million)
Table 91. Asia PARP Inhibitors for Cancer Revenue by Application (2024-2029) & (US$ Million)
Table 92. Asia PARP Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 93. Asia PARP Inhibitors for Cancer Revenue by Region (2018-2024) & (US$ Million)
Table 94. Asia PARP Inhibitors for Cancer Revenue by Region (2024-2029) & (US$ Million)
Table 95. Asia PARP Inhibitors for Cancer Sales by Region (2018-2024) & (K Units)
Table 96. Asia PARP Inhibitors for Cancer Sales by Region (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Type (2018-2024) & (K Units)
Table 98. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Type (2024-2029) & (K Units)
Table 99. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Type (2018-2024) & (US$ Million)
Table 100. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Type (2024-2029) & (US$ Million)
Table 101. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Application (2018-2024) & (K Units)
Table 102. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Application (2024-2029) & (K Units)
Table 103. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Application (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Application (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 106. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Country (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue by Country (2024-2029) & (US$ Million)
Table 108. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Country (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales by Country (2024-2029) & (K Units)
Table 110. AstraZeneca Company Information
Table 111. AstraZeneca Description and Major Businesses
Table 112. AstraZeneca PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. AstraZeneca PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. AstraZeneca Recent Developments
Table 115. Tesaro Company Information
Table 116. Tesaro Description and Major Businesses
Table 117. Tesaro PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Tesaro PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Tesaro Recent Developments
Table 120. Merck & Co Company Information
Table 121. Merck & Co Description and Major Businesses
Table 122. Merck & Co PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Merck & Co PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Merck & Co Recent Developments
Table 125. Clovis Oncology Company Information
Table 126. Clovis Oncology Description and Major Businesses
Table 127. Clovis Oncology PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Clovis Oncology PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Clovis Oncology Recent Developments
Table 130. Pfizer Company Information
Table 131. Pfizer Description and Major Businesses
Table 132. Pfizer PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Pfizer PARP Inhibitors for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Pfizer Recent Developments
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. PARP Inhibitors for Cancer Distributors List
Table 138. PARP Inhibitors for Cancer Customers List
Table 139. PARP Inhibitors for Cancer Market Trends
Table 140. PARP Inhibitors for Cancer Market Drivers
Table 141. PARP Inhibitors for Cancer Market Challenges
Table 142. PARP Inhibitors for Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. PARP Inhibitors for Cancer Product Picture
Figure 2. Global PARP Inhibitors for Cancer Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global PARP Inhibitors for Cancer Market Share by Type in 2022 & 2029
Figure 4. Lynparza Product Picture
Figure 5. Zejula Product Picture
Figure 6. Rubraca Product Picture
Figure 7. Talzenna Product Picture
Figure 8. Other Product Picture
Figure 9. Global PARP Inhibitors for Cancer Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 10. Global PARP Inhibitors for Cancer Market Share by Application in 2022 & 2029
Figure 11. Ovarian Cancer
Figure 12. Breast Cancer
Figure 13. Other
Figure 14. PARP Inhibitors for Cancer Report Years Considered
Figure 15. Global PARP Inhibitors for Cancer Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global PARP Inhibitors for Cancer Revenue 2018-2029 (US$ Million)
Figure 17. Global PARP Inhibitors for Cancer Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 18. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2018-2029)
Figure 19. Global PARP Inhibitors for Cancer Sales 2018-2029 ((K Units)
Figure 20. Global PARP Inhibitors for Cancer Sales Market Share by Region (2018-2029)
Figure 21. US & Canada PARP Inhibitors for Cancer Sales YoY (2018-2029) & (K Units)
Figure 22. US & Canada PARP Inhibitors for Cancer Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Europe PARP Inhibitors for Cancer Sales YoY (2018-2029) & (K Units)
Figure 24. Europe PARP Inhibitors for Cancer Revenue YoY (2018-2029) & (US$ Million)
Figure 25. China PARP Inhibitors for Cancer Sales YoY (2018-2029) & (K Units)
Figure 26. China PARP Inhibitors for Cancer Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Asia (excluding China) PARP Inhibitors for Cancer Sales YoY (2018-2029) & (K Units)
Figure 28. Asia (excluding China) PARP Inhibitors for Cancer Revenue YoY (2018-2029) & (US$ Million)
Figure 29. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales YoY (2018-2029) & (K Units)
Figure 30. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue YoY (2018-2029) & (US$ Million)
Figure 31. The PARP Inhibitors for Cancer Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 32. The Top 5 and 10 Largest Manufacturers of PARP Inhibitors for Cancer in the World: Market Share by PARP Inhibitors for Cancer Revenue in 2022
Figure 33. Global PARP Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
Figure 35. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
Figure 36. Global PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
Figure 37. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
Figure 39. US & Canada PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
Figure 40. US & Canada PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
Figure 41. US & Canada PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
Figure 42. US & Canada PARP Inhibitors for Cancer Revenue Share by Country (2018-2029)
Figure 43. US & Canada PARP Inhibitors for Cancer Sales Share by Country (2018-2029)
Figure 44. U.S. PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 45. Canada PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 46. Europe PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
Figure 47. Europe PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
Figure 48. Europe PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
Figure 49. Europe PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
Figure 50. Europe PARP Inhibitors for Cancer Revenue Share by Country (2018-2029)
Figure 51. Europe PARP Inhibitors for Cancer Sales Share by Country (2018-2029)
Figure 52. Germany PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 53. France PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 54. U.K. PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 55. Italy PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 56. Russia PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 57. China PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
Figure 58. China PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
Figure 59. China PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
Figure 60. China PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
Figure 61. Asia PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
Figure 62. Asia PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
Figure 63. Asia PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
Figure 64. Asia PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
Figure 65. Asia PARP Inhibitors for Cancer Revenue Share by Region (2018-2029)
Figure 66. Asia PARP Inhibitors for Cancer Sales Share by Region (2018-2029)
Figure 67. Japan PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 68. South Korea PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 69. China Taiwan PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 70. Southeast Asia PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 71. India PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 72. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue Market Share by Type (2018-2029)
Figure 74. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue Market Share by Application (2018-2029)
Figure 76. Middle East, Africa and Latin America PARP Inhibitors for Cancer Revenue Share by Country (2018-2029)
Figure 77. Middle East, Africa and Latin America PARP Inhibitors for Cancer Sales Share by Country (2018-2029)
Figure 78. Brazil PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 79. Mexico PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 80. Turkey PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 81. Israel PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 82. GCC Countries PARP Inhibitors for Cancer Revenue (2018-2029) & (US$ Million)
Figure 83. PARP Inhibitors for Cancer Value Chain
Figure 84. PARP Inhibitors for Cancer Production Process
Figure 85. Channels of Distribution
Figure 86. Distributors Profiles
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries